Physician profile
Melissa Scott
NPI 1295376366
$1,747.93
in general payments reported to CMS, 2019-2025
16 companies · $443 in 2025
The $443 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $217 · 2022: $303 · 2023: $245 · 2024: $540 · 2025: $443.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,227.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $386.69 | 2021-2025 | Wainua, Farxiga, Brilinta |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $286.75 | 2021-2025 | Lifevest |
| Abiomed | $277.35 | 2024-2025 | Impella |
| Amgen INC. | $260.44 | 2022-2025 | Repatha, Repatha |
| Boston Scientific Corporation | $93.42 | 2021-2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $77.87 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $66.64 | 2021-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $60.12 | 2022-2024 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $51.40 | 2023-2025 | Camzyos, Eliquis |
| Actelion Pharmaceuticals US, INC. | $47.72 | 2024-2025 | Uptravi, Opsumit |
| Chiesi USA, INC. | $29.19 | 2025 | Juxtapid, Cleviprex, Kengreal |
| Phathom Pharmaceuticals, INC. | $28.55 | 2024-2025 | Voquezna |
| Kiniksa Pharmaceuticals International, Plc | $23.10 | 2024 | Arcalyst |
| Alnylam Pharmaceuticals INC. | $21.63 | 2025 | Onpattro |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.01 | 2024 | Jardiance |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Terumo Medical Corporation | $16.05 | 2024 | Angio-Seal, Glidesheath Slender |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Scott listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.